Quarterly ResultAug 6, 2026, 07:01 AM
Opus Genetics Q2 Net Loss $8.1M; OPGx-BEST1 Data Sept 2026; Cash to 2029
AI Summary
Opus Genetics reported a net loss of $8.1 million for Q2 2026, with R&D expenses increasing to $11.2 million. The company announced significant pipeline advancements, including expected topline data for OPGx-BEST1 in September 2026 and completed enrollment for the OPGx-LCA5 registrational trial with dosing planned for Q4 2026. Opus Genetics also confirmed a strong cash position of $88.8 million, providing a runway into 2029 to support multiple clinical inflection points.
Key Highlights
- Cash and cash equivalents totaled $88.8 million as of June 30, 2026.
- Company expects current cash resources to fund operations into 2029.
- OPGx-BEST1 Cohort 1 topline data expected in the second week of September 2026.
- OPGx-LCA5 registrational trial enrollment completed; dosing planned for Q4 2026.
- OPGx-RDH12 program expected to enter clinic in Q4 2026.
- Net loss for Q2 2026 was $8.1 million, or ($0.08) per basic share.
- Research and development expenses increased to $11.2 million in Q2 2026 from $6.0 million YoY.
- License and collaborations revenue was $0.8 million in Q2 2026, down from $2.9 million YoY.
Price Impact
More from IRD
Clinical Trial2d ago, 5:26 PM
Opus Genetics Presents Positive Clinical Data for OPGx-BEST1 and OPGx-LCA5 Gene Therapies
Quarterly ResultAug 6, 4:42 PM
Opus Genetics Reports Q2 Net Loss of $73.6M; Equity Turns Negative
Clinical TrialAug 3, 7:03 AM
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial